title: P-450 epoxygenase and NO synthase inhibitors reduce cerebral blood flow response to N-methyl-D-aspartate.
abstract: Epoxyeicosatrienoic acids are cerebral vasodilators produced in astrocytes by cytochrome P-450 epoxygenase activity. The P-450 inhibitor miconazole attenuates the increase in cerebral blood flow (CBF) elicited by glutamate. We evaluated whether epoxygenase activity is involved in the CBF response to activation of the N-methyl-D-aspartate (NMDA) receptor subtype by using two structurally distinct inhibitors, miconazole and N-methylsulfonyl-6-(2-propargyloxyphenyl) hexanamide (MS-PPOH), a selective epoxygenase substrate inhibitor. Drugs were delivered locally through microdialysis probes in striata of anesthetized rats. Local CBF was measured by hydrogen clearance and compared with CBF in contralateral striatum receiving vehicle. Microdialysis perfusion of NMDA doubled CBF and increased nitric oxide (NO) production estimated by recovery of labeled citrulline in the dialysate during labeled arginine infusion. Perfusion of miconazole or MS-PPOH blocked the increase in CBF without decreasing citrulline recovery. Perfusion of N(omega)-nitro-L-arginine decreased baseline CBF and inhibited the CBF response to NMDA. Perfusion of MS-PPOH did not inhibit the CBF response to sodium nitroprusside. We conclude that both the P-450 epoxygenase and NO synthase pathways are involved in the local CBF response to NMDA receptor activation, and that the signaling pathway may be more complex than simply NO diffusion from neurons to vascular smooth muscle.
authors.affiliation: Departments of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.
authors.forename: A
authors.initials: A
authors.lastname: Bhardwaj
authors.forename: F J
authors.initials: FJ
authors.lastname: Northington
authors.forename: J R
authors.initials: JR
authors.lastname: Carhuapoma
authors.forename: J R
authors.initials: JR
authors.lastname: Falck
authors.forename: D R
authors.initials: DR
authors.lastname: Harder
authors.forename: R J
authors.initials: RJ
authors.lastname: Traystman
authors.forename: R C
authors.initials: RC
authors.lastname: Koehler
mesh_terms: D000577:Amides / Q000494:pharmacology*; D000818:Animals; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D002956:Citrulline / Q000378:metabolism; D000090762:Cytochrome P-450 CYP2J2; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System; D004791:Enzyme Inhibitors / Q000494:pharmacology; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology*; D008297:Male; D008825:Miconazole / Q000494:pharmacology*; D017551:Microdialysis; D016202:N-Methylaspartate / Q000494:pharmacology*; D009569:Nitric Oxide / Q000096:biosynthesis; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors*; D019335:Nitroarginine / Q000494:pharmacology; D010105:Oxygenases / Q000037:antagonists & inhibitors*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000577:Amides; D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors; D018690:Excitatory Amino Acid Agonists; C121756:N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide; D019335:Nitroarginine; D002956:Citrulline; D009569:Nitric Oxide; D016202:N-Methylaspartate; D008825:Miconazole; D003577:Cytochrome P-450 Enzyme System; D010105:Oxygenases; D019001:Nitric Oxide Synthase; D000090762:Cytochrome P-450 CYP2J2